Gastrointestinal Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Anticancer Res. 2012 Sep;32(9):4157-61.
The current study aimed to assess the long-term efficacy of combination therapy with oral S-1, a fluoropyrimidine prodrug, plus irinotecan in previously untreated patients with metastatic colorectal cancer.
Between April 2004 and February 2005, 41 patients with previously untreated advanced or recurrent colorectal cancer were enrolled in the study. Chemotherapy consisted of oral administration in S-1 at 40 mg/m(2) twice daily on days 1 to 14 and intravenous infusion of irinotecan at 150 mg/m(2) on day 1 in a 21-day cycle.
The median patient follow-up was 78.0 months. The median survival time was 23.7 months, and the 2-year survival rate was 50%. The median time to tumor progression was 8.3 months.
The results of this long-term update confirmed that first-line combination therapy with oral S-1 plus irinotecan was effective in patients with metastatic colorectal cancer.
本研究旨在评估氟嘧啶前体药物 S-1 联合伊立替康治疗初治转移性结直肠癌患者的长期疗效。
2004 年 4 月至 2005 年 2 月，41 例初治晚期或复发性结直肠癌患者入组本研究。化疗方案为 S-1 口服，剂量为 40mg/m²，每日 2 次，第 1-14 天；伊立替康静脉滴注，剂量为 150mg/m²，第 1 天，每 21 天为 1 个周期。
中位患者随访时间为 78.0 个月。中位生存时间为 23.7 个月，2 年生存率为 50%。中位肿瘤进展时间为 8.3 个月。
本长期更新研究结果证实，S-1 联合伊立替康一线治疗转移性结直肠癌有效。
